Illinois is currently home to 2681 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Coflex PS3 Actual Conditions for Use Study
Recruiting
A 2 and 5 year evaluation of clinical outcomes in the treatment of degenerative spinal stenosis with concomitant low back pain by decompression with additional stabilization using the coflex® Interlaminar Technology for FDA Actual Conditions of Use Study.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: 01L_Northshore University Health System, Evanston, Illinois
Conditions: Spinal Stenosis Lumbar
Investigation of Multi-Family Therapy for Anorexia Nervosa
Recruiting
The proposed project is an intensive multi family therapy (MFT) intervention involving patients with anorexia nervosa and their families. MFT interventions are informed from the principles of the family based treatment (FBT)/family therapy for Anorexia Nervosa (FT-AN) models. This program will offer families in vivo/virtual support while connecting with other families to increase knowledge of eating disorders and develop skills related to successfully supporting their adolescent during difficult... Read More
Gender:
All
Ages:
Between 11 years and 18 years
Trial Updated:
01/02/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Anorexia Nervosa
Aspire2B Personalization Pilot Study Program
Recruiting
This non-randomized pilot study program is focused on assessing the technical characteristics of the Aspire2B mobile device application.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/02/2024
Locations: Remote, no facility visits. Managed by PepsiCo R&D Life Sciences, Chicago, Illinois
Conditions: App Proficiency, Behavior, Lifestyle
High Powered Stone Dusting vs. Fragmentation and Basketing at Time of Ureteroscopy
Recruiting
The purpose of this study is to determine the differences in stone free results, patient side effects, and patient satisfaction between dusting vs. basket extraction for kidney and ureteral stones (a kidney stone located in the tube between the kidney and bladder) 6 mm and greater in size undergoing ureteroscopic treatment. Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine. Basket extraction is when a small wire basket is used to r... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
01/02/2024
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Kidney Stone, Ureteral Stone
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Recruiting
At present, it is not clear whether performing a hip arthroscopy at the same time as a PAO improves patient outcomes after surgery compared to a PAO alone. This research project will randomize patients to receive either a PAO alone, or a PAO and a hip arthroscopy at the same time.
Gender:
All
Ages:
Between 16 years and 50 years
Trial Updated:
01/02/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Hip Dysplasia
BlueWind RENOVA iStim™ System for the Treatment of OAB
Recruiting
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
Gender:
Female
Ages:
Between 18 years and 80 years
Trial Updated:
12/29/2023
Locations: Comprehensive Urologic Care, Lake Barrington, Illinois
Conditions: Treatment of Patients Suffering From Overactive Bladder (OAB)
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
Recruiting
The human epidermal growth factor receptor 2 (HER2) regulates cell growth and survival. Approximately 15-20% of all breast cancers are HER2-positive, which are an aggressive and fast-growing subtype of breast cancer. This study will evaluate a new treatment using a potent Poly polymerase (PARP) inhibitor known as Niraparib. Niraparib will be combined with trastuzumab, a HER2-targeted agent, to evaluate the safety and tolerability in patients with metastatic HER2 positive breast cancer. It is ant... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/27/2023
Locations: University of Chicago, Chicago, Illinois
Conditions: Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Recruiting
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Robert H. Lurie Comprehensive Cancer Center of Northwestern Univeristy, Chicago, Illinois
Conditions: Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
Recruiting
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
12/21/2023
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: SCN8A Developmental and Epileptic Encephalopathy Syndrome
A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
Recruiting
FIREFLY-1 is an ongoing, Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known RAF alteration.
Gender:
All
Ages:
Between 6 months and 25 years
Trial Updated:
12/21/2023
Locations: Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Low-grade Glioma, Advanced Solid Tumor
Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD
Recruiting
Evaluation of the safety and efficacy of the reSept ASD Occluder to treat patients with clinically significant secundum atrial septal defect
Gender:
All
Ages:
84 years and below
Trial Updated:
12/21/2023
Locations: Advocate Children's Hospital, Oak Lawn, Illinois
Conditions: Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases, Congenital Abnormalities
Modifiers of Disease Severity in Cerebral Cavernous Malformations
Recruiting
Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches. CCMs are often caused by an inherited gene mutation (alteration) in one of three CCM genes (CCM1, CCM2, or CCM3). There is a wide range of disease severity even among family members with this disease, though the natural history has not been clearly described for this particular population. This study will continue to enroll and follow... Read More
Gender:
All
Ages:
All
Trial Updated:
12/19/2023
Locations: University of Chicago, Medicine and Biological Sciences, Chicago, Illinois
Conditions: Cavernous Angioma, Familial, Cerebral Cavernous Malformations, Cerebral Cavernous Hemangioma